{"name": "TESARO",
 "permalink": "tesaro",
 "crunchbase_url": "http://www.crunchbase.com/company/tesaro",
 "homepage_url": "http://tesarobio.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2010,
 "founded_month": 3,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "contact@tesarobio.com",
 "phone_number": "339.970.0900",
 "description": "",
 "created_at": "Sat May 29 03:03:04 UTC 2010",
 "updated_at": "Thu Mar 07 02:19:47 UTC 2013",
 "overview": "\u003Cp\u003EFounded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.  The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients.  TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications.  Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012.  TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion.  TESARO is headquartered in Waltham, Massachusetts.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       32],
      "assets/images/resized/0008/8913/88913v1-max-150x150.jpg"],
     [[250,
       54],
      "assets/images/resized/0008/8913/88913v1-max-250x250.jpg"],
     [[312,
       68],
      "assets/images/resized/0008/8913/88913v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Co-Founder, CEO",
    "person":
     {"first_name": "Lonnie",
      "last_name": "Moulde",
      "permalink": "lonnie-moulde",
      "image": null}},
   {"is_past": false,
    "title": "President, CSO and co-founder",
    "person":
     {"first_name": "Mary",
      "last_name": "Lynne Hedley",
      "permalink": "mary-lynne-hedley",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Rick",
      "last_name": "Rodgers",
      "permalink": "rick-rodgers",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$252M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://onbiovc.com/tesaro-inc-series-a-60m/",
    "source_description": "Tesaro, Inc.: Series A $60M",
    "raised_amount": 60000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 5,
    "funded_day": 28,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "New Enterprise Associates",
         "permalink": "new-enterprise-associates",
         "image":
          {"available_sizes":
            [[[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-150x150.png"],
             [[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-250x250.png"],
             [[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "b",
    "source_url": "http://www.finsmes.com/2011/06/tesaro-secures-101m-series-financing.html?utm_source=feedburner\u0026utm_medium=feed\u0026utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29",
    "source_description": "TESARO Secures $101M in Series B Financing",
    "raised_amount": 101000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 6,
    "funded_day": 21,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Kleiner Perkins Caufield \u0026 Byers",
         "permalink": "kleiner-perkins-caufield-byers",
         "image":
          {"available_sizes":
            [[[150,
               150],
              "assets/images/resized/0001/0998/10998v8-max-150x150.jpg"],
             [[250,
               250],
              "assets/images/resized/0001/0998/10998v8-max-250x250.jpg"],
             [[450,
               450],
              "assets/images/resized/0001/0998/10998v8-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "New Enterprise Associates",
         "permalink": "new-enterprise-associates",
         "image":
          {"available_sizes":
            [[[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-150x150.png"],
             [[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-250x250.png"],
             [[150,
               110],
              "assets/images/resized/0001/5083/15083v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "InterWest Partners",
         "permalink": "interwest-partners",
         "image":
          {"available_sizes":
            [[[117,
               56],
              "assets/images/resized/0002/9316/29316v1-max-150x150.png"],
             [[117,
               56],
              "assets/images/resized/0002/9316/29316v1-max-250x250.png"],
             [[117,
               56],
              "assets/images/resized/0002/9316/29316v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "T. Rowe Price",
         "permalink": "t-rowe-price",
         "image":
          {"available_sizes":
            [[[150,
               51],
              "assets/images/resized/0003/0264/30264v1-max-150x150.png"],
             [[185,
               63],
              "assets/images/resized/0003/0264/30264v1-max-250x250.png"],
             [[185,
               63],
              "assets/images/resized/0003/0264/30264v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Pappas Ventures",
         "permalink": "pappas-ventures",
         "image":
          {"available_sizes":
            [[[150,
               131],
              "assets/images/resized/0004/9245/49245v1-max-150x150.png"],
             [[164,
               144],
              "assets/images/resized/0004/9245/49245v1-max-250x250.png"],
             [[164,
               144],
              "assets/images/resized/0004/9245/49245v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "post_ipo_equity",
    "source_url": "http://www.fiercebiotech.com/story/tesaro-pockets-91m-big-financing-major-cancer-trials-continue/2013-03-06?utm_source=rss\u0026utm_medium=rss",
    "source_description": "Tesaro pockets $91M in big financing as major cancer trials continue",
    "raised_amount": 91000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2013,
    "funded_month": 3,
    "funded_day": 6,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "1000 Winter St",
    "address2": "Suite #3300",
    "zip_code": "02451",
    "city": "Waltham",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "has signed a deal with Miami-based OPKO Health Inc. that will bring the Boston firm exclusive rights to develop, manufacture, commercialize and distribute rolapitant, a cancer-related treatment",
    "stoned_year": 2010,
    "stoned_month": 12,
    "stoned_day": 14,
    "source_url": "http://www.masshightech.com/stories/2010/12/13/daily25-Biotech-startup-Tesaro-lands-licensing-deal-for-cancer-treatment.html",
    "source_text": null,
    "source_description": "Biotech startup Tesaro lands licensing deal for cancer treatment",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "TESARO",
      "permalink": "tesaro"}},
   {"description": "landed an exclusive licensing deal with Amgen Inc., in which the Boston company will hold rights to Amgen\u00e2\u20ac\u2122s Anaplastic Lymphoma Kinase (ALK) technology",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 22,
    "source_url": "http://www.masshightech.com/stories/2011/03/21/daily19-Tesaro-buys-rights-to-Amgen-lung-cancer-tech-program.html",
    "source_text": null,
    "source_description": "Tesaro buys rights to Amgen lung cancer tech program",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "TESARO",
      "permalink": "tesaro"}},
   {"description": "Tesaro seeks $86.2M IPO",
    "stoned_year": 2012,
    "stoned_month": 3,
    "stoned_day": 26,
    "source_url": "http://www.masshightech.com/stories/2012/03/26/daily9-Tesaro-seeks-862M-IPO.html",
    "source_text": "",
    "source_description": "Tesaro seeks $86.2M IPO",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "TESARO",
      "permalink": "tesaro"}}],
 "ipo":
  {"valuation_amount": 86250000.0,
   "valuation_currency_code": "USD",
   "pub_year": 2012,
   "pub_month": 3,
   "pub_day": 23,
   "stock_symbol": "NASDAQ:TSRO"},
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        79],
       "assets/images/resized/0008/8912/88912v1-max-150x150.jpg"],
      [[250,
        132],
       "assets/images/resized/0008/8912/88912v1-max-250x250.jpg"],
      [[450,
        238],
       "assets/images/resized/0008/8912/88912v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}